FOR US, IT’S PERSONAL
Timothy T. Goodnow, PhD
President & CEO
“Diabetes is one of the spaces where there is truly is an individual at the end of your product…that makes it feel much more personal, so much more worthwhile.
That’s why I love hiring people with diabetes because they really get it.”
Dr. Goodnow joined the Senseonics Board of Directors in December 2010 and on March 1, 2011 became President & CEO. Dr. Goodnow was most recently with Abbott Diabetes Care where he was Vice President of Technical Operations. Prior to that, he held positions at TheraSense, Verax Biomedical, Dade Behring, and Baxter Healthcare. Dr. Goodnow has led the successful development of a number of FDA-approved glucose monitoring systems and insulin pumps.
He holds a PhD and BS in Chemistry from the University of Miami.
Chief Financial Officer
In his role as Chief Financial Officer (CFO), Jon is committed to increasing shareholder value and providing sound financial leadership to build the future of Senseonics.
Jon has a demonstrated history in the Private Equity industry. He has extensive experience in corporate finance, business development, entrepreneurship, venture capital, and leveraged finance within the healthcare and business services industries. Prior to joining Senseonics, Jon served in operational roles as the CFO at Edelman Financial Services (a Hellman and Friedman portfolio company) where he was responsible for Corporate Development, M&A, FP&A, Tax, Planner Economics, and Internal Controls. Prior to Edelman, Jon was a Managing Director for almost 15 years in the Private Equity Group at American Capital and a Managing Director at Thayer Capital Partners.
Jon holds a BA in Political Science from the Johns Hopkins University and an MBA from the Stanford Graduate School of Business.
Mukul Jain, PhD
Chief Operating Officer
Mukul is responsible for overseeing Quality, Regulatory, Product Development and Global Operations - including manufacturing and supply chain.
Prior to joining Senseonics, Mukul spent 13 years at Medtronic working on active implantable devices in CRDM and Neuromodulation space. He was responsible for managing the development of Neurostimulator systems in spinal cord stimulation and sacral nerve stimulation. Prior to that, he worked at Medtronic Energy and Components Center developing various critical components used across Medtronic’s implantable devices.
Mukul earned his MBA from Carlson School of Management at the University of Minnesota, a PhD in chemical engineering from the University of South Carolina and a B.Tech. from Indian Institute of Technology, Kanpur.
Francine R. Kaufman, MD
Chief Medical Officer
"As a pediatric endocrinologist for 40 years, I have cared for and met thousands of children and families with diabetes. I am continually humbled by what they do every day to stay healthy and well, regardless of age. It is my hope that I can help reduce their burden and improve their outcomes…and just simply make it all easier and less demanding for each of them to achieve optimal glucose control. That's why I do what I do…each and every day."
As Chief Medical Officer, Dr. Kaufman is dedicated to helping drive the innovation platform and the clinical value proposition of the Eversense CGM system. As one of the world’s leading endocrinologists, she brings a deep understanding of the global medical, research, and clinical diabetes community. Her track record of applying novel technologies to advance diabetes care for patients make her ideally suited for her role.
Dr. Kaufman’s career spans almost 40 years in diabetes care. She is a dedicated pediatric endocrinologist and has served as director of the Comprehensive Childhood Diabetes Center, and head of the Center for Endocrinology, Diabetes and Metabolism at Children’s Hospital Los Angeles. Dr. Kaufman is also a Distinguished Professor Emerita of Pediatrics and Communications at the Keck School of Medicine and the Annenberg School of Communications of the University of Southern California. She was formerly the president of the American Diabetes Association, chair of the National Diabetes Education Program, and elected to the National Academy of Medicine. She is the author of more than 250 scientific manuscripts and numerous books, including Diabesity: The Obesity-Diabetes Epidemic That Threatens America and the ADA’s Insulin Pumps and Continuous Glucose Monitoring: A User’s Guide to Effective Diabetes Management. Dr. Kaufman is an active philanthropist working with numerous organizations and charities around the world aimed at improving the lives of people with diabetes. She was also an advisor to the Governor on the California Initiative on Health, Fitness and Obesity. Most recently Dr. Kaufman served as Chief Medical Officer and Vice President of Global Clinical, Regulatory and Medical Affairs at Medtronic Diabetes.
Dr. Kaufman received a BA from Northwestern University and was the Valedictorian of her class at Chicago Medical School.
VP & GM of US region
“When I share with my kids what I do, I tell them I get an opportunity every day to help people, and because it’s a long-term solution - 90 days in the US right now, we feel like it’s a major step forward.”
Mr. Gill was named Vice President and General Manager of the U.S. Region in April of 2017. From May 2015 to August of 2016 Mr. Gill served as Vice President - Americas Region for Medtronic Diabetes. Mr. Gill has more than 25 years of healthcare experience and during this time served in a number of managerial capacities with Medtronic, including when the first ever CGM was introduced. Mr. Gill was instrumental in commercializing CGM integrated and augmented systems into the U.S., Latin America and Canada. Mr. Gill received his BS in International Business and World Trade from the State University of New York at Buffalo.
VP & GM of Global Operations
“I think I have the best job in the world, because I get to be part of a team that introduces Eversense. So, I’m thankful!”
Prior to joining Senseonics, Ms. Panlilio served as Vice-President of Sales and Marketing for Arkal Medical (continuous glucose monitoring) and VeraLight (type 2 diabetes diagnostic). At TheraSense/Abbott Diabetes Care, she directed the worldwide strategic commercialization of the FreeStyle Navigator® continuous glucose monitoring system. She was also with LifeScan, a Johnson and Johnson company, where she led the marketing efforts of the company’s hospital glucose monitoring business unit, championed its first joint product venture with Inverness Medical (Selfcare), and led the sales and marketing teams in its Asia Pacific business. Additionally, she managed the development and successful commercialization of several new products, including the best-selling OneTouch® System. Ms. Panlilio received her BS degree from San Jose State University in Business Administration.
Abhi Chavan, PhD
Vice President, Engineering, R & D
Dr. Chavan brings more than 30 years of experience in research, development, and engineering, most recently at Medtronic Diagnostics as Senior Director, R&D. Previously he was Vice President of Research, Product Development and Manufacturing Operations for Corventis, where he guided development of wearable, mobile cardiac health products. Dr. Chavan also spent several years at Boston Scientific in Research & Product Development, managing projects related to the design of Class III implanted Cardiac Rhythm Management devices.
Prior to that, he held various management and engineering positions with General Motors and Delphi Electronics, as well as software and design engineering positions at Siemens A.G. and Coherent Research Inc. Dr. Chavan has published widely in the field of medical devices, automotive systems, circuits and sensors, and has more than 50 worldwide patents issued. He is a Senior member of the IEEE and EMBS. He received his BSEE (valedictorian) from Maharaja Sayajirao University, Baroda-India; his MSEE from Syracuse University, NY; and a PhD in Electrical Engineering from University of Michigan, Ann Arbor.
Katherine Tweden, PhD
Vice President, Clinical Sciences
Dr. Katherine S. Tweden is an experienced executive with more than 25 years in research, clinical, and regulatory who most recently guided a novel, class-three active implantable obesity medical device from invention through FDA approval at EnteroMedics Inc. as one of the co-inventors and founders. Beginning in 1990, she worked in the medical device industry in R&D roles in the fields of coronary vascular disease, heart valve disease, and periodontal ligament regeneration at HeartStent Corporation, St. Jude Medical, Inc., and W.L. Gore and Associates. Dr. Tweden has more than 60 patents and publications in related fields. Dr. Tweden received a BA in Chemistry from Gustavus Adolphus College, MS and PhDs in Biomedical Engineering from Iowa State University, and post-doctorates in oral biology and surface chemistry from State University of New York at Buffalo.